Sestre, a women’s wellness startup specialising in the production of supplements for fertility and hormonal dysfunctions based on the Mediterranean diet, announces that it has received a follow-on investment of EUR 400,000 from CDP Venture Capital, thanks to the support of Terra Next, the acceleration programme of the CDP Venture Capital National Network in which it was selected from the first batch, and the Fondo Imprese Femminili of MiMiT. The round was joined by new figures, such as Lifegate Way, who are strategic for Sestre’s growth and its path of innovation.
“The new investment by CDP highlights the importance of our project and the goals we have achieved,’ says Sestre’s CEO Sabrina Fiorentino (in the photo with the team) in a note. ‘With this new contribution, we are ready to achieve new goals, in particular that of consolidating the Italian market and expanding abroad, starting immediately from Spain. It is a journey that will continue thanks to the trust placed in us, but also thanks to the cohesion and passion of our all-female team, and to all those who believe in our mission: to revolutionise the treatment of infertility and hormonal dysfunctions with the active ingredients of the Mediterranean diet, a symbol of Made in Italy.”
Over the past two years, the Trinitapoli-based startup has scientifically validated its nutraceutical supplements through clinical studies, obtaining the Epigenox invention patent. This is also thanks to the advice and commitment of more than 250 specialised doctors involved in the project, who have helped more than four thousand women through treatments to assist hormonal dysfunctions and inflammatory diseases, but also to improve immune defences, rebalance the microbiota, and above all to accompany women towards conception.
With a network of more than ten of the largest pharmaceutical distributors in Italy, in the last year Sestre has also started to support women through a digital health service, which allows them to personalise therapies, monitor symptomatic improvements and maximise results. The company is currently developing a tech platform based on machine learning algorithms that can predict the risk of infertility based on the health status of the microbiota. This innovation will add important parameters to the data that Sestre collects, allowing patterns to be identified that will further improve the effectiveness of treatments and guide the development of new, increasingly customised and innovative products.
ALL RIGHTS RESERVED ©